Literature DB >> 21038080

Focal macular electroretinograms after photodynamic therapy combined with intravitreal bevacizumab.

Kohei Ishikawa1, Hiroaki Nishihara, Shinsuke Ozawa, Chang-Hua Piao, Yasuki Ito, Mineo Kondo, Hiroko Terasaki.   

Abstract

BACKGROUND: Retinal function is transiently depressed after photodynamic therapy (PDT) alone. One of the reasons for this functional impairment is a reduction of choroidal circulation caused by the PDT. The purpose of this study was to determine whether PDT combined with intravitreal bevacizumab (PDT+IVB) can reduce or prevent the transient impaired macular function. In addition, we examined whether a significant correlation existed between the changes in the focal macular electroretinograms (FMERGs), optical coherence tomography (OCT)-determined morphology, and changes in choroidal circulation.
METHODS: Thirty-eight eyes that were treated by full fluence PDT+IVB were studied. FMERGs, OCT, and indocyanine green angiography (ICGA) were performed before and after the PDT. The intensity of the diffuse fluorescence within the PDT site was measured by densitometry (I/N ratio).
RESULTS: The macula was significantly thinner 1 week after PDT+IVB (P < 0.01). The mean a- and b-wave amplitudes of the FMERGs were not significantly decreased 1 week after PDT+IVB. The mean b-wave amplitudes 3 months after PDT+IVB were significantly increased (P < 0.01). The I/N ratio of ICGA 3 months after PDT+IVB was 0.88 ± 0.1. The correlation between the FMERGs and I/N ratio was not significant.
CONCLUSION: The use of IVB with PDT mitigates the reduction of the FMERGs and reduces the macular thickness soon after PDT, regardless of the degree of impairment of choroidal circulation caused by PDT. Finally, the macular retinal function 3 months after PDT+IVB were better than that before the treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21038080     DOI: 10.1007/s00417-010-1548-x

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  38 in total

1.  [Testing central retinal function with multifocal electroretinography before and after photodynamic therapy].

Authors:  K Rüther; K Breidenbach; R Schwartz; A Hassenstein; G Richard
Journal:  Ophthalmologe       Date:  2003-06       Impact factor: 1.059

2.  Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.

Authors: 
Journal:  Ophthalmology       Date:  2001-05       Impact factor: 12.079

3.  Transitions of multifocal electroretinography following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Chengguo Zuo; Feng Wen; Jiaqing Li; Yan Liu; Meng Li
Journal:  Doc Ophthalmol       Date:  2009-01-31       Impact factor: 2.379

4.  Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.

Authors:  Albert J Augustin; Ursula Schmidt-Erfurth
Journal:  Ophthalmology       Date:  2005-12-19       Impact factor: 12.079

Review 5.  [Studies of local macular ERG].

Authors:  Y Miyake
Journal:  Nippon Ganka Gakkai Zasshi       Date:  1988-09

6.  Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration.

Authors:  Albert J Augustin; Ursula Schmidt-Erfurth
Journal:  Am J Ophthalmol       Date:  2006-04       Impact factor: 5.258

7.  Triamcinolone acetonide suppresses early proangiogenic response in retinal pigment epithelial cells after photodynamic therapy in vitro.

Authors:  R Obata; A Iriyama; Y Inoue; H Takahashi; Y Tamaki; Y Yanagi
Journal:  Br J Ophthalmol       Date:  2006-09-20       Impact factor: 4.638

8.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

9.  Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration.

Authors:  Markus S Ladewig; Stefanie E Karl; Victoria Hamelmann; Hans-Martin Helb; Hendrik P N Scholl; Frank G Holz; Nicole Eter
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-15       Impact factor: 3.117

10.  Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab.

Authors:  Swaantje Peters; Peter Heiduschka; Sylvie Julien; Focke Ziemssen; Heike Fietz; Karl Ulrich Bartz-Schmidt; Ulrich Schraermeyer
Journal:  Am J Ophthalmol       Date:  2007-04-23       Impact factor: 5.258

View more
  5 in total

1.  Effects of three consecutive monthly intravitreal injection of ranibizumab for polypoidal choroidal vasculopathy in Korea.

Authors:  Young Gun Park; Seungbum Kang; Young Jung Roh
Journal:  Int J Ophthalmol       Date:  2015-04-18       Impact factor: 1.779

Review 2.  Functional optical coherence tomography of retinal photoreceptors.

Authors:  Xincheng Yao; Taeyoon Son; Tae-Hoon Kim; Yiming Lu
Journal:  Exp Biol Med (Maywood)       Date:  2018-11-27

3.  Short-term focal macular electroretinogram of eyes treated by aflibercept & photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Kei Takayama; Hiroki Kaneko; Keiko Kataoka; Shinji Ueno; Piao Chang-Hua; Yasuki Ito; Hiroko Terasaki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-08-18       Impact factor: 3.117

4.  Comparison between 1-year outcomes of aflibercept with and without photodynamic therapy for polypoidal choroidal vasculopathy: Retrospective observation study.

Authors:  Kei Takayama; Hiroki Kaneko; Keiko Kataoka; Kyoko Hattori; Eimei Ra; Taichi Tsunekawa; Hiroshi Fukukita; Fuminori Haga; Yasuki Ito; Hiroko Terasaki
Journal:  PLoS One       Date:  2017-05-03       Impact factor: 3.240

5.  Cross-sectional pupillographic evaluation of relative afferent pupillary defect in age-related macular degeneration.

Authors:  Kei Takayama; Yasuki Ito; Hiroki Kaneko; Yosuke Nagasaka; Taichi Tsunekawa; Tadasu Sugita; Hiroko Terasaki
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.